In: Commentaries
The “from-quality-to-system” pendulum
December 20, 2021by Anton Bespalov and Anja Gilis In the dialectics world of the German philosopher Georg Hegel, quantitative changes transform into qualitative…
Read MoreOf peer review and data sharing
November 3, 2021We (preclinical) learn from the Big Brother (clinical). For example, they recognize the risks of bias in study design, conduct and…
Read More“Don’t cut the tree you are sitting on!”
November 3, 2021According to a recent press release from the European parliament, an EU-wide action plan is requested with ambitious and achievable objectives for phasing-out…
Read MoreHow to See More Clearly in the Lab?
June 16, 2021When you can see the world clearly, it’s easy to get where you want to go: You might still get where…
Read MoreAducanumab’s approval is not FDA’s failure, it is our failure
June 16, 2021On June 7, 2021, the FDA approved aducanumab, an amyloid beta-directed monoclonal antibody indicated for the treatment of Alzheimer’s disease.However, most…
Read MorePseudoreplication in Physiology – more means less
March 30, 2021Many publications leave it to readers to guess whether reported data are based on independent biological replicates (e.g. number of animals)…
Read MoreLet’s discuss reproducibility – the new “Journal for Reproducibility in Neuroscience”
March 30, 2021by Plinio Cabrera Casarotto, PhD,Editor-in-Chief JRepNeurosci The replicability of results is a cornerstone of science. We can only rely on the outcomes…
Read MoreFive rules for evidence communication
December 18, 2020Communicating science is difficult. We were told to tell exciting stories around our scientific discoveries – and it is certainly true…
Read MoreThe Costs of Competitiveness
December 18, 2020In one of the recent Nature issues, there was a piece called “France’s reforms: the costs of competitiveness”. In a nutshell,…
Read MoreA time to cast away stones, and a time to gather stones together
December 18, 2020Since the seminal paper by Laura Bohn 20 years ago, expectations have built up that biased mu-opioid receptor agonists will deliver what we…
Read More